Gwern performs a life-extension cost-benefit of metformin, the diabetes drug that may have more general anti-aging properties, and finds that metformin use is probably “profitable” for a 30-year-old.
Gwern performs a life-extension cost-benefit of metformin, the diabetes drug that may have more general anti-aging properties, and finds that metformin use is probably “profitable” for a 30-year-old.
Posted in Science | No Comments »